Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics ...

Zscaler trades at an EV/Rev ratio of 8, its historical low, offering significant mean reversion potential vs. its 5Y median ...

My name is Leonard and I'm the technical operator for today's call. [Operator Instructions] One last remark, if you would like to follow the presented slides on your ...

Baystreet.ca News Commentary — The convergence of precision medicine, novel mechanisms, and regulatory support is driving a renaissance in neuropsychiatric drug development1. Federal ...

In practical terms, this means much of Vancouver’s future land-use debate is being relocated from hundreds of individual hearings to a single city-wide framework. Yet cities rarely emerge from a ...

Tesla Inc TSLA struggled with weakening demand in several global markets throughout 2025, a trend that could challenge the electric-vehicle maker's lofty valuation. One market expert argues the stock ...

Early GO decision reached in CAPTIVATE ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants ...

Asking caregivers if they are concerned about clutter or possible hoarding may help identify neurocognitive disorders, according to a study published in The Journal of Neuropsychiatry and Clinical ...

At a media briefing following the launch of Xpeng’s second-generation vision-language-action (VLA) model, He Xiaopeng, ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Xenon Pharmaceuticals Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Study of 2 million people shows genetic risk for nine major mental illnesses including schizophrenia and anxiety, varies by age and treatment, often lacking specificity.